Fed Circ. Rejects Amgen Bid For DNA Patent

Law360, New York (April 3, 2009, 12:00 AM EDT) -- In a decision that raises the bar for biotechnology companies to protect their work on DNA sequencing, Amgen Inc. has lost a federal appeals court fight to obtain a patent related to so-called natural killer cells in bone marrow.

In a widely watched case, the U.S. Court of Appeals for the Federal Circuit on Friday upheld the U.S. Patent and Trademark Office's rejection of the application by two Amgen scientists — Marek Z. Kubin and Raymond G. Goodwin — for a patent related to sequencing a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.